Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.
By Peter Jüni, L. Nartey, S. Reichenbach, R. Sterchi, Paul A. Dieppe, Matthias Egger. The Lancet, 2004
899 citations recorded by the source corpus.
Subfields: Biochemistry, Cardiology and Cardiovascular Medicine, Pharmacology
View Paper: https://www.semanticscholar.org/paper/d728e70856609bc0898a8c43aa36313709bc3abc
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Pharmacology
Citations in the corpus
- Lipid signalling in disease (2008, background): “Treatment of rheumatoid disease with the selective COX2 inhibitor rofecoxib (Vioxx) was associated with serious cardiovascular complication”
- Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. (2006, methodology): “91) with rofecoxib doses above 25 mg/d; but there were insufficient data from the randomized trials to make this calculation.(6,41) In contrast to the evidence from the randomized trials, we found no increase in risk with commonly used doses of celecoxib.”
- GRADE guidelines: 7. Rating the quality of evidence--inconsistency. (2011, neutral): “82, I5 0%) [10].”
- Efficacy and Tolerability of Long-Acting Injectable Naltrexone for Alcohol Dependence: A Randomized Controlled Trial (2005, result): “Our study, with nearly 5 times as many rofecoxibexposed case-patients with MI as reported in the recent cumulative meta-analysis (38), provides additional evidence that the use of rofecoxib is associated with an increased risk for acute MI.”
- [Guidelines on the management of stable angina pectoris: executive summary]. (2006, result): “An increased risk of suffering fatal or non-fatal MI was also found in a meta-analysis of other randomized trials with rofecoxib.(147) Thus, there are indications from studies with several COX-2 inhibitors that they may increase the risk of coronary thrombotic events in patient populations with diff”
- Limitations of Animal Studies for Predicting Toxicity in Clinical Trials (2019, background): “An estimated 88,000 people suffered heart attacks after taking Vioxx and 38,000 died (19).”
- Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods (2014, background): “On the other hand, if statistical significance has been reached, then clinical significance must be assessed [11,12,16,73,74].”
- Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer (2017, background): “Although they do not affect the gastrointestinal system, some of these compounds, such as rofecoxib, which was withdrawn from the market in 2004, can produce cardiovascular toxicity [236].”